Trials / Completed
CompletedNCT01386125
A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) in the Treatment of Nasal Polyps (Protocol No. P05604)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 748 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effectiveness and safety of MFNS in improving nasal congestion/obstruction and in reducing bilateral nasal polyps.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone Furoate Nasal Spray (MFNS) | MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks |
| DRUG | Placebo for MFNS | Two sprays in each nostril BID for up to 16 weeks |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2011-06-30
- Last updated
- 2024-05-21
- Results posted
- 2013-12-19
Source: ClinicalTrials.gov record NCT01386125. Inclusion in this directory is not an endorsement.